Illumina, Inc., and Eli Lilly and Company | springermedicine.com Skip to main content

Medical Journals

Webcasts & Webinars

Podcasts

CME & eLearning

Newsletters

Key Specialties

Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery

Congress Coverage

2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress

Clinical Collections

Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Springer Medicine

ADVANCED SEARCH

Springer Medicine

JAVASCRIPT NEEDED

Please enable JavaScript on your browser, so that you can use all features of this website.

INTERNET EXPLORER IS NO LONGER SUPPORTED

Your version of Internet Explorer is no longer supported by this system. Please install one of the following browsers: Microsoft Edge, Safari, Chrome or Firefox

Illumina, Inc., and Eli Lilly and Company

Home
Congress Coverage
Clinical Collections
- Advances in Alzheimer’s
About Springer Medicine
Key Specialties

Springer Medicine delivers all the latest knowledge you need, helping you to be the best doctor you can.

Version: 0.3589.0